Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
Potassium phosphates (dibasic and monobasic formulation) is an intravenous electrolyte replacement therapy administered as a solution. It is indicated for correcting potassium and phosphate deficiencies in patients requiring parenteral nutrition or those with documented electrolyte imbalances. The drug works by directly replenishing depleted intracellular and extracellular potassium and phosphate ions.
Peak lifecycle stage indicates stable market positioning with established hospital formulary presence; commercial teams are focused on maintaining market share rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on potassium phosphates offers stability in a mature, non-volatile market segment with established hospital relationships and predictable demand patterns. Career trajectories emphasize operational excellence, hospital account development, and supply chain optimization rather than launch excitement or expansion strategy.
Worked on POTASSIUM PHOSPHATES at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo